Sinil Pharmaceutical Co. Ltd
Sinil Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers pharmaceutical products for various indications, such as pain reliever, anti-inflammatory, hyperlipidemia, skin disease, and folic acid deficiency; and general/specialty drugs, veterinary drugs, and OEM products for various diseases. The company also provides cosmetics, incl… Read more
Market Cap & Net Worth: Sinil Pharmaceutical Co. Ltd (012790)
Sinil Pharmaceutical Co. Ltd (KQ:012790) has a market capitalization of $47.37 Million (₩69.36 Billion) as of March 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #23471 globally and #1265 in its home market, demonstrating a 0.17% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sinil Pharmaceutical Co. Ltd's stock price ₩6000.00 by its total outstanding shares 11559561 (11.56 Million).
Sinil Pharmaceutical Co. Ltd Market Cap History: 2015 to 2026
Sinil Pharmaceutical Co. Ltd's market capitalization history from 2015 to 2026. Data shows change from $67.35 Million to $47.37 Million (-4.38% CAGR).
Index Memberships
Sinil Pharmaceutical Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.85 Billion | 0.02% | #619 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.85 Billion | 0.02% | #619 of 1384 |
Weight: Sinil Pharmaceutical Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Sinil Pharmaceutical Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sinil Pharmaceutical Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Sinil Pharmaceutical Co. Ltd's market cap is 0.00 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.00x
Sinil Pharmaceutical Co. Ltd's market cap is 0.00 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $67.35 Million | $44.70 Billion | $8.76 Billion | 0.00x | 0.01x |
| 2016 | $64.06 Million | $50.21 Billion | $10.04 Billion | 0.00x | 0.01x |
| 2017 | $57.94 Million | $50.94 Billion | $8.20 Billion | 0.00x | 0.01x |
| 2018 | $46.70 Million | $53.28 Billion | $5.71 Billion | 0.00x | 0.01x |
| 2019 | $49.28 Million | $60.65 Billion | $7.26 Billion | 0.00x | 0.01x |
| 2020 | $165.45 Million | $61.44 Billion | $7.54 Billion | 0.00x | 0.02x |
| 2021 | $86.68 Million | $61.75 Billion | $6.68 Billion | 0.00x | 0.01x |
| 2022 | $66.26 Million | $80.01 Billion | $12.16 Billion | 0.00x | 0.01x |
| 2023 | $60.87 Million | $89.14 Billion | $13.64 Billion | 0.00x | 0.00x |
| 2024 | $50.76 Million | $89.44 Billion | $14.30 Billion | 0.00x | 0.00x |
Competitor Companies of 012790 by Market Capitalization
Companies near Sinil Pharmaceutical Co. Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Sinil Pharmaceutical Co. Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Sinil Pharmaceutical Co. Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Sinil Pharmaceutical Co. Ltd's market cap moved from $67.35 Million to $ 47.37 Million, with a yearly change of -4.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩47.37 Million | -1.15% |
| 2025 | ₩47.92 Million | -5.60% |
| 2024 | ₩50.76 Million | -16.60% |
| 2023 | ₩60.87 Million | -8.13% |
| 2022 | ₩66.26 Million | -23.56% |
| 2021 | ₩86.68 Million | -47.61% |
| 2020 | ₩165.45 Million | +235.77% |
| 2019 | ₩49.28 Million | +5.51% |
| 2018 | ₩46.70 Million | -19.39% |
| 2017 | ₩57.94 Million | -9.56% |
| 2016 | ₩64.06 Million | -4.89% |
| 2015 | ₩67.35 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Sinil Pharmaceutical Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $47.37 Million USD |
| MoneyControl | $47.37 Million USD |
| MarketWatch | $47.37 Million USD |
| marketcap.company | $47.37 Million USD |
| Reuters | $47.37 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.